Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Phase 2
51
about 2.7 years
18–55
2 sites in TX
About this study
Researchers are testing a treatment with autologous HB-adMSCs to see if it can improve brain structure, cognitive function, and reduce inflammation after traumatic brain injury. The trial will last about 989 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Autologous HB-adMSCs
- 2.Take Normal Saline
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Alanine aminotransferase, Aspartate aminotransferase, Creatinine, Glucose
Secondary: Brief Symptom Inventory 18, Interleukin 6, PET/DT-MRI (positron emission tomography/Diffusion tensor-Magnetic resonance imaging), TBI (Traumatic Brain Injury) Quality of Life Questionnaires, Whole brain MRI (Magnetic resonance imaging)